鉴定一种对耐抗生素粪肠球菌和屎肠球菌具有致死活性的广谱活性噬菌体裂解酶。
Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium.
作者信息
Yoong Pauline, Schuch Raymond, Nelson Daniel, Fischetti Vincent A
机构信息
Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, 1230 York Ave., New York, NY 10021, USA.
出版信息
J Bacteriol. 2004 Jul;186(14):4808-12. doi: 10.1128/JB.186.14.4808-4812.2004.
Abstract
Enterococcus faecalis and Enterococcus faecium infections are increasingly difficult to treat due to high levels of resistance to antibiotics. PlyV12, a bacteriophage lytic enzyme, was isolated and shown to effectively kill both E. faecalis and E. faecium (including vancomycin-resistant strains), as well as other human pathogens. We propose its development and use as an alternative therapeutic tool.
摘要
粪肠球菌和屎肠球菌感染由于对抗生素的高度耐药性而越来越难以治疗。噬菌体裂解酶PlyV12已被分离出来，并显示出能有效杀死粪肠球菌和屎肠球菌（包括耐万古霉素菌株）以及其他人类病原体。我们建议将其开发并用作一种替代治疗工具。
相似文献
1
Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium.
J Bacteriol. 2004 Jul;186(14):4808-12. doi: 10.1128/JB.186.14.4808-4812.2004.
2
[Antibiotic susceptibility analysis of Enterococcus spp. isolated from urine].
Przegl Lek. 2004;61(5):473-6.
3
Time-kill profiles of Enterococcus to antibiotics used for intravitreal therapy.
Ophthalmic Surg Lasers. 1998 Apr;29(4):295-9.
4
Differences in antibiotic resistance patterns of Enterococcus faecalis and Enterococcus faecium strains isolated from farm and pet animals.
Antimicrob Agents Chemother. 2001 May;45(5):1374-8. doi: 10.1128/AAC.45.5.1374-1378.2001.
5
Antibiotic resistant fecal isolates of Enterococci among unselected patients outside the clinical sector: an epidemiological study from Southern Germany.
Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):275-7. doi: 10.1002/pds.1167.
6
Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
J Microbiol Immunol Infect. 2008 Apr;41(2):124-9.
7
Multiple antibiotic resistances of Enterococcus isolates from raw or sand-filtered sewage.
Appl Microbiol Biotechnol. 2007 Feb;74(2):493-500. doi: 10.1007/s00253-006-0668-z. Epub 2006 Nov 22.
8
Isolation and characterization of a novel Enterococcus faecalis bacteriophage phiEF24C as a therapeutic candidate.
FEMS Microbiol Lett. 2008 Jan;278(2):200-6. doi: 10.1111/j.1574-6968.2007.00996.x.
9
In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
Int J Antimicrob Agents. 2009 Jul;34(1):21-4. doi: 10.1016/j.ijantimicag.2008.12.011. Epub 2009 Feb 24.
10
Characterization of lytic enzyme open reading frame 9 (ORF9) derived from Enterococcus faecalis bacteriophage phiEF24C.
Appl Environ Microbiol. 2011 Jan;77(2):580-5. doi: 10.1128/AEM.01540-10. Epub 2010 Nov 19.
引用本文的文献
1
Characterization of LysBM1, a novel high-penetrating phage lysin targeting enterohemorrhagic .
Front Vet Sci. 2025 Jul 11;12:1631293. doi: 10.3389/fvets.2025.1631293. eCollection 2025.
2
Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.
MedComm (2020). 2025 Jul 13;6(7):e70280. doi: 10.1002/mco2.70280. eCollection 2025 Jul.
3
Deep learning-guided structural analysis of a novel bacteriophage KPP105 against multidrug-resistant .
Comput Struct Biotechnol J. 2025 May 1;27:1827-1837. doi: 10.1016/j.csbj.2025.04.032. eCollection 2025.
4
Beyond Antibiotics: Exploring the Potential of Bacteriophages and Phage Therapy.
Phage (New Rochelle). 2024 Dec 18;5(4):186-202. doi: 10.1089/phage.2024.0005. eCollection 2024 Dec.
5
The Unique Capability of Endolysin to Tackle Antibiotic Resistance: Cracking the Barrier.
J Xenobiot. 2025 Jan 25;15(1):19. doi: 10.3390/jox15010019.
6
Characterization of the host specificity of the SH3 cell wall binding domain of the staphylococcal phage 88 endolysin.
Arch Microbiol. 2025 Jan 29;207(2):47. doi: 10.1007/s00203-025-04242-1.
7
Bacteriophage Therapy as a Promising Alternative for Antibiotic-Resistant : Advances and Challenges.
Antibiotics (Basel). 2024 Nov 23;13(12):1120. doi: 10.3390/antibiotics13121120.
8
resensitization of multidrug-resistant clinical isolates of and through phage-antibiotic synergy.
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0074024. doi: 10.1128/aac.00740-24. Epub 2024 Dec 19.
9
Characterization of Two Novel Endolysins from Bacteriophage PEF1 and Evaluation of Their Combined Effects on the Control of Planktonic and Biofilm Cells.
Antibiotics (Basel). 2024 Sep 13;13(9):884. doi: 10.3390/antibiotics13090884.
10
Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens.
Molecules. 2024 Aug 27;29(17):4065. doi: 10.3390/molecules29174065.
本文引用的文献
1
Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia.
Infect Immun. 2003 Nov;71(11):6199-204. doi: 10.1128/IAI.71.11.6199-6204.2003.
2
Novel method to control pathogenic bacteria on human mucous membranes.
Ann N Y Acad Sci. 2003 Apr;987:207-14. doi: 10.1111/j.1749-6632.2003.tb06050.x.
3
A bacteriolytic agent that detects and kills Bacillus anthracis.
Nature. 2002 Aug 22;418(6900):884-9. doi: 10.1038/nature01026.
4
C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates.
Mol Microbiol. 2002 Apr;44(2):335-49. doi: 10.1046/j.1365-2958.2002.02889.x.
5
Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.
Science. 2001 Dec 7;294(5549):2170-2. doi: 10.1126/science.1066869.
6
Phage antibacterials make a comeback.
Nat Biotechnol. 2001 Aug;19(8):734-5. doi: 10.1038/90777.
7
Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme.
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4107-12. doi: 10.1073/pnas.061038398. Epub 2001 Mar 20.
8
Vancomycin-resistant enterococci.
Clin Microbiol Rev. 2000 Oct;13(4):686-707. doi: 10.1128/CMR.13.4.686.
9
Biological roles of two new murein hydrolases of Streptococcus pneumoniae representing examples of module shuffling.
Res Microbiol. 2000 Jul-Aug;151(6):437-43. doi: 10.1016/s0923-2508(00)00172-8.
10
Pathogenesis of group A streptococcal infections.
Clin Microbiol Rev. 2000 Jul;13(3):470-511. doi: 10.1128/CMR.13.3.470.
Zotero 插件